Active, not recruitingPhase 1NCT06461286

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

Studying Autosomal dominant optic atrophy

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: PYC Therapeutics
Principal Investigator: Sreenivasu Mudumba, PhD
PYC Therapeutics
Intervention: PYC-001(drug)
Enrollment: 18 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2026

Study locations (2)

Save Sight Institute - Sydney Eye Hospital, Sydney, New South Wales, Australia
Center for Eye Research Australia (CERA), East Melbourne, Victoria, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06461286 on ClinicalTrials.gov

Other trials for Autosomal dominant optic atrophy

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1, PHASE2NCT06970106
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy
PYC Therapeutics

See all trials for Autosomal dominant optic atrophy →

← Back to all trials